Article
Radiology, Nuclear Medicine & Medical Imaging
Li-Jen Wang, Masahiro Jinzaki, Cher Heng Tan, Young Taik Oh, Hiroshi Shinmoto, Chau Hung Lee, Nayana U. Patel, Silvia D. Chang, Antonio C. Westphalen, Chan Kyo Kim
Summary: This study investigated the use of radiological studies and biopsy for the diagnosis and staging of prostate cancer (PCA) in Asian countries through an international survey. The results revealed the diverse technical details and availability of imaging and biopsy methods for PCA evaluation. The findings highlight the importance of providing an educational program for Asian radiologists to promote standardized evidence-based imaging approaches for the diagnosis and staging of PCA.
KOREAN JOURNAL OF RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Min Je Kim, Sung Yoon Park
Summary: The study aimed to develop a multivariate prebiopsy nomogram using clinical and bpMRI parameters to estimate the probability of csPCa. The results showed that the developed nomogram had a significantly higher AUC compared to individual parameters, with a mean AUC of 0.888 in the 5-fold cross-validation. ADCR was found to enhance the role of bpMRI in detecting csPCa.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chu Hyun Kim, Chan Kyo Kim, Jung Jae Park, Sung Yoon Park, Young Cheol Yoon
Summary: The study demonstrates that concurrent SB with MRTB based on PI-RADS v2 can yield a higher detection rate of clinically significant cancer in patients with suspected PCa.
EUROPEAN RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tobias Penzkofer, Anwar R. Padhani, Baris Turkbey, Masoom A. Haider, Henkjan Huisman, Jochen Walz, Georg Salomon, Ivo G. Schoots, Jonathan Richenberg, Geert Villeirs, Valeria Panebianco, Olivier Rouviere, Vibeke Berg Logager, Jelle Barentsz
Summary: Artificial intelligence is crucial for the successful deployment of community-wide MRI-driven prostate cancer diagnosis by ensuring high specificity, biopsy avoidance, and integration into radiologists' workflow. Further development efforts are needed to make AI systems as clinical decision-making tools for a wider adoption of the MRI-directed approach.
EUROPEAN RADIOLOGY
(2021)
Article
Urology & Nephrology
Stephan Tschirdewahn, Manuel Wiesenfarth, David Bonekamp, Lukas Puellen, Henning Reis, Andrej Panic, Claudia Kesch, Christopher Darr, Jochen Hess, Francesco Giganti, Caroline M. Moore, Nika Guberina, Michael Forsting, Axel Wetter, Boris Hadaschik, Jan Philipp Radtke
Summary: This study evaluated the detection rates of significant prostate cancer (sPC) using different biopsy approaches and found that target saturation (TS) fusion biopsies detected significantly more sPC lesions compared to targeted biopsies (TB) and extended systematic biopsies (SB). TS also detected more low-risk PC lesions and had higher detection rates at a per-patient level.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Health Care Sciences & Services
Alon Lazarovich, Tomer Drori, Dorit E. Zilberman, Orith Portnoy, Zohar A. Dotan, Barak Rosenzweig
Summary: We quantified the additive diagnostic value of systematic biopsy using in-bore magnetic resonance-guided prostate biopsy. Adding systematic biopsy increased the capability of diagnosing both clinically significant and non-clinically significant prostate cancer.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Urology & Nephrology
Adam Kinnaird, Nitin K. Yerram, Luke O'Connor, Wayne Brisbane, Vidit Sharma, Ryan Chuang, Rajiv Jayadevan, Michael Ahdoot, Michael Daneshvar, Alan Priester, Merdie Delfin, Elizabeth Tran, Danielle E. Barsa, Anthony Sisk, Robert E. Reiter, Ely Felker, Steve Raman, Lorna Kwan, Peter L. Choyke, Maria J. Merino, Bradford J. Wood, Baris Turkbey, Peter A. Pinto, Leonard S. Marks
Summary: This study aimed to investigate the upgrading rate in prostate cancer active surveillance (AS) when biopsy guided by magnetic resonance imaging (MRGBx) is used. The results showed that when AS begins and follows with MRGBx, the upgrading rate is greater when the tumor is initially present within a magnetic resonance imaging lesion or when pathology is GG2.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Daniele D'agostino, Carlo Casablanca, Federico Mineo Bianchi, Paolo Corsi, Daniele Romagnoli, Marco Giampaoli, Cristian Fiori, Riccardo Schiavina, Eugenio Brunocilla, Walter Artibani, Angelo Porreca
Summary: Comparing MRI fusion and in-bore MRI guided biopsy approaches in detecting prostate cancer, it was found that in the in-bore MRI group, more biopsy cores were taken but the number of positive cores was relatively lower.
MINERVA UROLOGY AND NEPHROLOGY
(2021)
Article
Urology & Nephrology
Fabio Zattoni, Giancarlo Marra, Veeru Kasivisvanathan, Jeremy Grummet, Rohan Nandurkar, Guillaume Ploussard, Jonathan Olivier, Peter K. Chiu, Massimo Valerio, Paolo Gontero, Hongqian Guo, Junlong Zhuang, Francesco Barletta, Riccardo Leni, Mark Frydenberg, Daniel Moon, Uri Hanegbi, Adam Landaumailto, Ross Snow, Maria Apfelbeck, Alexander Kretschmer, Roderick van den Bergh, Giacomo Novara, Alberto Briganti, Fabrizio Dal Moro, Giorgio Gandaglia
Summary: This multicenter cohort study compared the detection rate of significant prostate cancer using transperineal MRI-targeted prostate biopsy (TP-TBx) and transrectal TBx. The results showed that TP-TBx had a higher detection rate of prostate cancer and clinically significant prostate cancer compared to transrectal TBx. TP-TBx allows for better cancer grade definition and risk assessment, which is important in decision making and patient counseling for further treatment.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Atsuko Fujihara, Tsuyoshi Iwata, Aliasger Shakir, Alessandro Tafuri, Giovanni E. Cacciamani, Karanvir Gill, Akbar Ashrafi, Osamu Ukimura, Mihir Desai, Vinay Duddalwar, Mariana S. Stern, Manju Aron, Suzanne L. Palmer, Inderbir S. Gill, Andre Luis Abreu
Summary: Multiparametric magnetic resonance imaging (mpMRI) is useful in predicting prostate cancer reclassification, especially for lesions with PI-RADS >= 3. Serial MRI can effectively predict pathological progression.
Review
Oncology
Byung Kwan Park
Summary: This article introduces the new TRUS protocols, imaging features, and biopsy techniques that radiologists or urologists need to know for prostate cancer detection and treatment, as well as assessing the necessity of systematic biopsy for improving biopsy outcomes.
Review
Urology & Nephrology
Pawel Rajwa, Benjamin Pradere, Fahad Quhal, Keiichiro Mori, Ekaterina Laukhtina, Nicolai A. Huebner, David D'Andrea, Aleksandra Krzywon, Sung Ryul Shim, Pascal A. Baltzer, Raphaele Renard-Penna, Michael S. Leapman, Shahrokh F. Shariat, Guillaume Ploussard
Summary: The study evaluated the diagnostic estimates of serial prostate MRI for PCa progression during AS, suggesting that MRI alone is not accurate enough to reliably rule out or rule in prostate cancer progression. Other clinical factors and biomarkers are needed to tailor the intensity of follow-up biopsies.
Review
Oncology
Srinath Kotamarti, Rajan T. Gupta, Bangchen Wang, Denis Seguier, Zoe Michael, Dylan Zhang, Michael R. Abern, Jiaoti Huang, Thomas J. Polascik
Summary: There is uncertainty in how to proceed when targeted prostate biopsies of suspicious mpMRI lesions return without clinically significant prostate cancer. Possible error sources include mpMRI read, mpMRI-ultrasound fusion, biopsy technique, and histologic classification. To address this issue, we implemented a quality improvement initiative.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Review
Medicine, General & Internal
Lorenzo Cereser, Laura Evangelista, Gianluca Giannarini, Rossano Girometti
Summary: In recent years, prostate magnetic resonance imaging (MRI) has become essential in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can prevent unnecessary biopsies, a positive examination prompts targeted biopsy samples, leading to increased csPCa diagnosis with high sensitivity and negative predictive value. The limitations of MRI have sparked discussions on how to stratify biopsy decisions and management based on patient risk and accurately estimate it with clinical and/or imaging findings. Next-generation imaging techniques such as radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) are expanding their indications in primary staging and diagnosis, offering increased sensitivity and serving as problem-solving tools in indeterminate MRI cases. This review summarizes the current evidence on the role of prostate MRI and PSMA-PET in the primary diagnosis of csPCa and their potential interactions.
Review
Radiology, Nuclear Medicine & Medical Imaging
Jung Jae Park, Chan Kyo Kim
Summary: This article reviews recent literature on the diagnostic value of pre-biopsy prostate MRI as a triage tool and discusses unresolved issues regarding the paradigm shift in the diagnosis of prostate cancer.
KOREAN JOURNAL OF RADIOLOGY
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Anwar R. Padhani, Ivo G. Schoots, Baris Turkbey, Gianluca Giannarini, Jelle O. Barentsz
EUROPEAN RADIOLOGY
(2021)
Editorial Material
Urology & Nephrology
Hendrik Van Poppel, Renee Hogenhout, Peter Albers, Roderick C. N. van den Bergh, Jelle O. Barentsz, Monique J. Roobol
Article
Radiology, Nuclear Medicine & Medical Imaging
Melline G. M. Schilham, Patrik Zamecnik, Bastiaan M. Prive, Bas Israel, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah, Martin Gotthardt
Summary: Accurate assessment of lymph node metastases in prostate cancer patients is crucial. PSMA PET/CT and nano-MRI are imaging modalities with high potential for identifying LN metastases. This study compared the results of these modalities, finding that nano-MRI detected more suspicious LNs, especially smaller ones, across all anatomical regions of the pelvis. It suggests that nano-MRI could complement PSMA PET/CT in imaging PCa patients, but further investigation is needed.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Letter
Radiology, Nuclear Medicine & Medical Imaging
Clare M. C. Tempany-Afdhal, Anwar Padhani, Jelle Barentsz, Jeffrey Weinreb
Article
Oncology
Bastiaan M. Prive, Steffie M. B. Peters, Constantijn H. J. Muselaers, Inge M. van Oort, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Mark W. Konijnenberg, Patrik Zamecnik, Maike J. M. Uijen, Melline G. M. Schilham, Annemarie Eek, Tom W. J. Scheenen, J. Fred Verzijlbergen, Winald R. Gerritsen, Niven Mehra, Linda G. W. Kerkmeijer, Robert J. Smeenk, Diederik M. Somford, Jean-Paul A. Van Basten, Sandra Heskamp, Jelle O. Barentsz, Martin Gotthardt, J. Alfred Witjes, James Nagarajah
Summary: In this prospective study, Lu-177-PSMA appeared to be a feasible and safe treatment modality for patients with low-volume metastatic hormone-sensitive prostate cancer, showing good treatment effect and minimal adverse events.
CLINICAL CANCER RESEARCH
(2021)
Article
Urology & Nephrology
Barbara Lily Therese Rijksen, Floris J. Pos, Maarten C. C. M. Hulshof, Robin W. M. Vernooij, Hanneke Jansen, George van Andel, Bart P. Wijsman, Diederink M. Somford, Martijn B. Busstra, Reindert J. A. van Moorselaar, Christina A. Hulsbergen-van de Kaa, Geert J. L. H. van Leenders, Paul Hamberg, Franchette van den Berkmortel, Jurgen J. Futterer, Lambertus A. Kiemeney, Inge M. van Oort, Katja K. H. Aben
Summary: The study found that less than one-third of intermediate-risk PCa patients treated with EBRT receive ADT in the Netherlands, with significant variation in prescription between institutions. In high-risk patients, the majority received recommended ADT, but there is room for improvement in guideline adherence.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Urology & Nephrology
Bas Israel, Jos Immerzeel, Marloes van der Leest, Gerjon Hannink, Patrik Zamecnik, Joyce Bomers, Ivo G. Schoots, Jean-Paul Van Basten, Frans Debruyne, Inge van Oort, Michiel Sedelaar, Jelle Barentsz
Summary: The study evaluated the outcomes of pre-biopsy MRI pathways in biopsy-naive men with suspicion of prostate cancer in routine clinical practice. The results showed that pre-biopsy MRI can be used as a decision tool without compromising cancer detection rates and with a higher biopsy avoidance rate. There were comparable cancer detection and complication rates between TR- and TP-MRDB.
Article
Oncology
D. J. H. Baas, M. Schilham, R. Hermsen, J. M. S. de Baaij, H. J. E. J. Vrijhof, R. J. Hoekstra, J. P. M. Sedelaar, H. V. N. Kusters-Vandevelde, M. Gotthardt, C. H. W. Wijers, J. P. van Basten, D. M. Somford
Summary: This study indicates that preoperative PSMA-PET/CT may be a valuable tool for patient counseling for RARP and ePLND, as it can predict the risk of postoperative BCP and early BCR.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Emmy Boerrigter, Guillemette E. Benoist, Inge M. van Oort, Gerald W. Verhaegh, Anton F. J. de Haan, Onno van Hooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter de Mol, Tineke J. Smilde, Diederik M. Somford, Paul Hamberg, Vincent O. Dezentje, Niven Mehra, Nielka P. van Erp, Jack A. Schalken
Summary: The evaluation of treatment in metastatic castration-resistant prostate cancer is challenging, and there is an urgent need for biomarkers to distinguish short-term survivors from long-term survivors shortly after treatment initiation. Research has shown that adding miR-375 and KLK3 (at baseline and 1 month) to standard clinical parameters produces the best prediction model for survival assessment.
Article
Health Care Sciences & Services
Martijn P. A. Starmans, Li Shen Ho, Fokko Smits, Nick Beije, Inge de Kruijff, Joep J. de Jong, Diederik M. Somford, Egbert R. Boeve, Ed Te Slaa, Evelyne C. C. Cauberg, Sjoerd Klaver, Antoine G. van der Heijden, Carl J. Wijburg, Addy C. M. van de Luijtgaarden, Harm H. E. van Melick, Ella Cauffman, Peter de Vries, Rens Jacobs, Wiro J. Niessen, Jacob J. Visser, Stefan Klein, Joost L. Boormans, Astrid A. M. van der Veldt
Summary: The study aimed to evaluate the ability of CT-based radiomics to differentiate between pN+ and pN0 disease in patients with clinical stage cT2-T4aN0-N1M0 MIBC. The results showed that radiomics features did not significantly differentiate between pN+ and pN0 disease, and the radiomics models performed no better than random guessing.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Meeting Abstract
Urology & Nephrology
Diederik Baas, Melline Schilham, Joost de Baaij, Eric Vrijhof, Robert Hoekstra, Rick Hermsen, Diederik Somford, Jean-Paul van Basten
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Malou C. P. Kuppen, Hans M. Westgeest, Alphonsus J. M. van den Eertwegh, Reindert J. A. van Moorselaar, Inge M. van Oort, Juleon L. L. M. Coenen, A. C. M. Fons van den Bergh, Niven Mehra, Diederik M. Somford, Andre M. Bergman, Daan Ten Bokkel Huinink, Laurent Fossion, Maud M. Geenen, Mathijs P. Hendriks, Addy C. M. van de Luijtgaarden, Marco B. Polee, Nir Weijl, Agnes J. van de Wouw, Ronald de Wit, Carin A. Uyl-de Groot, Winald R. Gerritsen
Summary: The study examined the treatment outcomes of ART2 in mCRPC patients and found that the effectiveness of ART2 seemed to be low, regardless of the interposition of other LPDs between ART1 and ART2. Results indicated that the PSA response rate and treatment duration of ART2 were relatively short.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Meeting Abstract
Urology & Nephrology
D. J. H. Baas, J. J. H. Beck, J-P. A. Van Basten, J. P. M. Sedelaar, H. J. E. J. Vrijhof, H. H. E. Van Melick, H. M. Bruins, P. J. Van Leeuwen, R. P. W. F. Wijn, Busch P. Ostergren, D. M. Somford
Meeting Abstract
Urology & Nephrology
D. J. H. Baas, M. G. M. Schilham, J. M. S. De Baaij, H. J. E. J. Vrijhof, R. J. Hoekstra, J. P. M. Sedelaar, R. Hermsen, D. M. Somford, J. P. A. Van Basten
Meeting Abstract
Urology & Nephrology
M. G. M. Schilham, R. Hermsen, H. Kusters-Vandevelde, T. Scheenen, M. Gotthardt, D. M. Somford, J. P. M. Sedelaar, M. Rijpkema